|
Few data are available on the incidence, characteristics, treatment, and prognosis of inflammatory bowel disease-associated colorectal cancer (CRC) in population-based cohorts. Dr Laurent Peyrin-Biroulet from France identified all cases of inflammatory bowel disease-associated colorectal cancer among the 19,451 new cases of colorectal cancer recorded in the Burgundy digestive cancer registry between 1976 and 2008. The incidence rates were age-standardized according to the world standard population. Prognosis was determined using univariate and multivariate relative survival. The research team identified 38 inflammatory bowel disease-associated colorectal cancer.
The mean age at colorectal cancer diagnosis was greater for patients without inflammatory bowel disease than those with inflammatory bowel disease. | | IBD-associated colorectal cancer per 100,000 was 0.11 for men | | Inflammatory Bowel Disease |
The doctors found that distributions of gender, stage at presentation, location, and histological type of colorectal cancer did not differ from those of sporadic cases. The overall world age-standardized incidence of inflammatory bowel disease-associated colorectal cancer per 100,000 was 0.11 for men, and 0.06 for women. The researchers reported that only age was independently associated with inflammatory bowel disease-associated colorectal cancer. Treatment modalities did not differ between inflammatory bowel disease and non-inflammatory bowel disease patients. The team found that a 5-year relative survival was 52% in non-inflammatory bowel disease patients, and 41% in inflammatory bowel disease patients. After adjustment for age, gender, and stage at diagnosis, the excess hazard of death was about 2 times higher in inflammatory bowel disease than in non-IBD patients. Dr Peyrin-Biroulet's team concluded that "Apart from age, the characteristics of inflammatory bowel disease-associated colorectal cancer were similar to those of non-inflammatory bowel disease colorectal cancer." "The prognosis of colorectal cancer may be poorer in patients with inflammatory bowel disease than in those without inflammatory bowel disease."
| 
Email this page to a colleague
